Literature DB >> 9124828

Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases.

F Blanche1, B Cameron, F X Bernard, L Maton, B Manse, L Ferrero, N Ratet, C Lecoq, A Goniot, D Bisch, J Crouzet.   

Abstract

Staphylococcus aureus gyrA and gyrB genes encoding DNA gyrase subunits were cloned and coexpressed in Escherichia coli under the control of the T7 promoter-T7 RNA polymerase system, leading to soluble gyrase which was purified to homogeneity. Purified gyrase was catalytically indistinguishable from the gyrase purified from S. aureus and did not contain detectable amounts of topoisomerases from the E. coli host. Topoisomerase IV subunits GrlA and GrlB from S. aureus were also expressed in E. coli and were separately purified to apparent homogeneity. Topoisomerase IV, which was reconstituted by mixing equimolar amounts of GrlA and GrlB, had both ATP-dependent decatenation and DNA relaxation activities in vitro. This enzyme was more sensitive than gyrase to inhibition by typical fluoroquinolone antimicrobial agents such as ciprofloxacin or sparfloxacin, adding strong support to genetic studies which indicate that topoisomerase IV is the primary target of fluoroquinolones in S. aureus. The results obtained with ofloxacin suggest that this fluoroquinolone could also primarily target gyrase. No cleavable complex could be detected with S. aureus gyrase upon incubation with ciprofloxacin or sparfloxacin at concentrations which fully inhibit DNA supercoiling. This suggests that these drugs do not stabilize the open DNA-gyrase complex, at least under standard in vitro incubation conditions, but are more likely to interfere primarily with the DNA breakage step, contrary to what has been reported with E. coli gyrase. Both S. aureus gyrase-catalyzed DNA supercoiling and S. aureus topoisomerase IV-catalyzed decatenation were dramatically stimulated by potassium glutamate or aspartate (500- and 50-fold by 700 and 350 mM glutamate, respectively), whereas topoisomerase IV-dependent DNA relaxation was inhibited 3-fold by 350 mM glutamate. The relevance of the effect of dicarboxylic amino acids on the activities of type II topoisomerases is discussed with regard to the intracellular osmolite composition of S. aureus.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9124828      PMCID: PMC163609     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Roles of topoisomerase IV and DNA gyrase in DNA unlinking during replication in Escherichia coli.

Authors:  E L Zechiedrich; N R Cozzarelli
Journal:  Genes Dev       Date:  1995-11-15       Impact factor: 11.361

2.  Antibiotics that resist resistance.

Authors:  R F Service
Journal:  Science       Date:  1995-11-03       Impact factor: 47.728

Review 3.  Molecular mechanisms of DNA gyrase inhibition by quinolone antibacterials.

Authors:  L L Shen
Journal:  Adv Pharmacol       Date:  1994

4.  Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition.

Authors:  K Hoshino; A Kitamura; I Morrissey; K Sato; J Kato; H Ikeda
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

Review 5.  Topoisomerase poisons: harnessing the dark side of enzyme mechanism.

Authors:  S J Froelich-Ammon; N Osheroff
Journal:  J Biol Chem       Date:  1995-09-15       Impact factor: 5.157

Review 6.  Structure and mechanism of DNA topoisomerases.

Authors:  D B Wigley
Journal:  Annu Rev Biophys Biomol Struct       Date:  1995

7.  Decatenation activity of topoisomerase IV during oriC and pBR322 DNA replication in vitro.

Authors:  H Peng; K J Marians
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

8.  Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.

Authors:  L Ferrero; B Cameron; B Manse; D Lagneaux; J Crouzet; A Famechon; F Blanche
Journal:  Mol Microbiol       Date:  1994-08       Impact factor: 3.501

9.  Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions.

Authors:  H Peng; K J Marians
Journal:  J Biol Chem       Date:  1993-11-15       Impact factor: 5.157

10.  Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates.

Authors:  R J Belland; S G Morrison; C Ison; W M Huang
Journal:  Mol Microbiol       Date:  1994-10       Impact factor: 3.501

View more
  48 in total

1.  Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus.

Authors:  Y Dong; X Zhao; J Domagala; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

2.  Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli.

Authors:  S Bagel; V Hüllen; B Wiedemann; P Heisig
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

3.  Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones.

Authors:  X S Pan; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

4.  Purification and characterization of recombinant Staphylococcus haemolyticus DNA gyrase and topoisomerase IV expressed in Escherichia coli.

Authors:  Joel C Bronstein; Stacey L Olson; Kristin LeVier; Mark Tomilo; Peter C Weber
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

5.  Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.

Authors:  Jacob Strahilevitz; Ari Robicsek; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

6.  Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.

Authors:  C M Bébéar; O Grau; A Charron; H Renaudin; D Gruson; C Bébéar
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

7.  Detection of grlA and gyrA mutations in 344 Staphylococcus aureus strains.

Authors:  T Wang; M Tanaka; K Sato
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

8.  Molecular characterization of the gene encoding the DNA gyrase A subunit of Streptococcus pneumoniae.

Authors:  D Balas; E Fernández-Moreira; A G De La Campa
Journal:  J Bacteriol       Date:  1998-06       Impact factor: 3.490

9.  Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound.

Authors:  Michelle M Butler; William A Lamarr; Kimberly A Foster; Marjorie H Barnes; Donna J Skow; Patrick T Lyden; Lauren M Kustigian; Chengxin Zhi; Neal C Brown; George E Wright; Terry L Bowlin
Journal:  Antimicrob Agents Chemother       Date:  2006-10-30       Impact factor: 5.191

10.  Quinolone resistance mutations in the GrlB protein of Staphylococcus aureus.

Authors:  M Tanaka; Y Onodera; Y Uchida; K Sato
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.